Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in the EU / 2025-523933-24-00
Authorised, recruiting Phase III

A Randomized, Open-label, Parallel-group Phase III Study to Evaluate the Efficacy, Safety, and Tolerability of Elecoglipron Compared with Oral Semaglutide in Adults with Type 2 Diabetes Mellitus (Eluminate-2)

2025-523933-24-00 · tracked via the Priya Life Science EU tracker
Sponsor
AstraZeneca AB
Sponsor type
Pharmaceutical company
Therapeutic area
Nutritional and Metabolic Diseases
Decision date
22/07/2026
Enrollment target
335
Sites
Poland, Hungary, Italy, Bulgaria, Germany

Condition studied

type 2 diabetes mellitus

Investigational medicinal product(s)

ElecoglipronRybelsus 9 mg tabletsRybelsus 4 mg tabletsRybelsus 1.5 mg tablets

Eligibility

Age group
18-64 years, 65+ years
Sex
Female, Male

Primary endpoint

Change from baseline to Week 52 in HbA1c (%)

Endpoint detail

Percent change from baseline to Week 52 in body weight, Change from baseline to Week 52 in body weight (kg), Achieved ≥ 5% weight loss from baseline at Week 52 and achieved HbA1c < 7% (53 mmol/mol) at Week 52, Achieved HbA1c ≤ 6.5% (48 mmol/mol) at Week 52, Achieved HbA1c < 7% (53 mmol/mol) at Week 52

Official registry record

This page summarises publicly available CTIS data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View 2025-523933-24-00 on CTIS ↗ ← All trials in the EU